397 related articles for article (PubMed ID: 36111769)
1. Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease.
Jing XZ; Yang HJ; Taximaimaiti R; Wang XP
Curr Neuropharmacol; 2023; 21(5):1224-1240. PubMed ID: 36111769
[TBL] [Abstract][Full Text] [Related]
2. Advances in dopamine receptor agonists for the treatment of Parkinson's disease.
Stocchi F; Torti M; Fossati C
Expert Opin Pharmacother; 2016 Oct; 17(14):1889-902. PubMed ID: 27561098
[TBL] [Abstract][Full Text] [Related]
3. An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease.
Cerri S; Blandini F
Expert Opin Pharmacother; 2020 Dec; 21(18):2279-2291. PubMed ID: 32804544
[TBL] [Abstract][Full Text] [Related]
4. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
Bezard E; Gray D; Kozak R; Leoni M; Combs C; Duvvuri S
CNS Neurol Disord Drug Targets; 2024; 23(4):476-487. PubMed ID: 36999711
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
6. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
7. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
Radad K; Gille G; Rausch WD
Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
[TBL] [Abstract][Full Text] [Related]
8. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes].
Szczudlik A; Rudzińska M
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S6-9. PubMed ID: 17941452
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of dopamine agonists in Parkinson's disease.
Lange KW
Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
[TBL] [Abstract][Full Text] [Related]
10. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease.
Ogawa N
Neurology; 1998 Aug; 51(2 Suppl 2):S13-20. PubMed ID: 9711975
[TBL] [Abstract][Full Text] [Related]
11. [Choosing a dopamine agonist in Parkinson's disease].
Bogucki A; Gajos A
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S14-21. PubMed ID: 17941454
[TBL] [Abstract][Full Text] [Related]
12. Dopamine agonist therapy in early Parkinson's disease.
Stowe RL; Ives NJ; Clarke C; van Hilten J; Ferreira J; Hawker RJ; Shah L; Wheatley K; Gray R
Cochrane Database Syst Rev; 2008 Apr; (2):CD006564. PubMed ID: 18425954
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonists in Parkinson's disease.
Yamamoto M; Schapira AH
Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D
Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
[TBL] [Abstract][Full Text] [Related]
15. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic substitution in Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2002 Oct; 3(10):1393-403. PubMed ID: 12387685
[TBL] [Abstract][Full Text] [Related]
17. Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
Zhang J; Tan LC
Curr Neuropharmacol; 2016; 14(4):356-63. PubMed ID: 26644151
[TBL] [Abstract][Full Text] [Related]
18. The safety of dopamine agonists in the treatment of Parkinson's disease.
Bonuccelli U; Ceravolo R
Expert Opin Drug Saf; 2008 Mar; 7(2):111-27. PubMed ID: 18324875
[TBL] [Abstract][Full Text] [Related]
19. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
[TBL] [Abstract][Full Text] [Related]
20. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
Mokhles MM; Trifirò G; Dieleman JP; Haag MD; van Soest EM; Verhamme KM; Mazzaglia G; Herings R; Luise Cd; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; Camp Gv; Zanettini R; Sturkenboom MC
Pharmacol Res; 2012 Mar; 65(3):358-64. PubMed ID: 22123498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
